<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mediators Inflamm</journal-id><journal-id journal-id-type="publisher-id">MI</journal-id><journal-title>Mediators of Inflammation</journal-title><issn pub-type="ppub">0962-9351</issn><issn pub-type="epub">1466-1861</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19197380</article-id><article-id pub-id-type="pmc">2633607</article-id><article-id pub-id-type="doi">10.1155/2008/407972</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Homocysteine May Involve in the Pathogenesis of  Behcet's Disease by Inducing Inflammation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kartal Durmazlar</surname><given-names>Selda Pelin</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Akgul</surname><given-names>Ahmet</given-names></name><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Eskioglu</surname><given-names>Fatma</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Dermatology, Diskapi Yildirim Beyazit Education and Research Hospital, Ministry of Health Ankara, 06110 Ankara, Turkey</aff><aff id="I2"><sup>2</sup>Department of Cardiovascular Surgery, Turkiye Yuksek Ihtisas Education and Research Hospital, Ministry of Health Ankara, 06100 Ankara, Turkey</aff><author-notes><corresp id="cor1">*Selda Pelin Kartal Durmazlar: <email>pelin@dr.com</email></corresp><fn fn-type="other"><p>Recommended by Dennis Daniel Taub</p></fn></author-notes><pub-date pub-type="ppub"><year>2008</year></pub-date><pub-date pub-type="epub"><day>1</day><month>2</month><year>2009</year></pub-date><volume>2008</volume><elocation-id>407972</elocation-id><history><date date-type="received"><day>1</day><month>8</month><year>2008</year></date><date date-type="rev-recd"><day>2</day><month>11</month><year>2008</year></date><date date-type="accepted"><day>17</day><month>11</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Selda Pelin Kartal Durmazlar et al.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>					<italic>Objective</italic>. Our aim was to evaluate the significance of homocysteine (Hcy) in Behcet's disease (BD) and the association of elevated Hcy levels associated with the indices of inflammation in BD. <italic>Methods</italic>. Untreated 70 patients with BD and 33 healthy individuals were included into the study. Hcy, tumor necrosis alpha (TNF-<italic>&#x003b1;</italic>), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were evaluated with respect to activity and specific individual clinical manifestations of the disease. <italic>Results</italic>. Hcy levels were found significantly elevated in active BD when compared to inactive BD and healthy controls. Hcy levels were found to have high correlation with the number of active clinical manifestations increased. A significant positive correlation was found between serum Hcy and TNF-<italic>&#x003b1;</italic> levels, CRP, and ESR. Hcy was found to be the best predictor of TNF-<italic>&#x003b1;</italic> among other parameters. <italic>Conclusion</italic>. Hcy may involve in the pathogenesis of BD by inducing inflammation.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. INTRODUCTION</title><p>In 1969, McCully first proposed homocysteine (Hcy) tobe a cause of cardiovascular disease due to the observation that patients withhomocystinuria, a metabolic disease which results in high Hcy levels, alsodisplayed atherosclerotic plaques at autopsies [<xref ref-type="bibr" rid="B1">1</xref>]. High levels of Hcy were associatedwith endothelial damage and oxidative stress [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>]. Currently, there is aclassification commonly used for the degree of hyperhomocysteinemia as follows:normal (5&#x02013;14 <italic>&#x003bc;</italic>mol/L), mild(15&#x02013;30 <italic>&#x003bc;</italic>mol/L), moderate (31&#x02013;100 <italic>&#x003bc;</italic>mol/L), andsevere (&#x0003e;100 <italic>&#x003bc;</italic>mol/L) [<xref ref-type="bibr" rid="B4">4</xref>]. As many epidemiologic studies supported, mildhyperhomocysteinemia was found risk factor for both venous and arterialthrombosis [<xref ref-type="bibr" rid="B5">5</xref>&#x02013;<xref ref-type="bibr" rid="B8">8</xref>]. Hcy is anintermediary sulphydryl-containing amino acid formed during the conversion of methionine tocysteine. Its sulphydryl group can cause direct endothelial cytotoxicity,inhibition of glutathione peroxidase and nitric oxide, interference withclotting factor, and oxidation of LDL [<xref ref-type="bibr" rid="B9">9</xref>]. Additionally, high levels of Hcycause lipid peroxidation, impaired vasomotor regulation, prothrombic surface,and, therefore, atherothrombogenesis [<xref ref-type="bibr" rid="B10">10</xref>].</p><p>Behcet'sdisease (BD), initially described by Behcet in 1937 [<xref ref-type="bibr" rid="B11">11</xref>], is a chronic relapsingvasculitis, involving both arteries and veins of various sizes. Thromboticcomplications have been reported in approximately 10&#x02013;40% of BDpatients [<xref ref-type="bibr" rid="B12">12</xref>]. Endothelial dysfunction due to inflammation is considered to bean important factor of thrombosis in BD. Homocysteine is reported to enhanceendothelial leukocyte interaction [<xref ref-type="bibr" rid="B13">13</xref>]. Some studies have shown thathyperhomocysteinemia might be assumed to be an independent and correctable riskfactor for thrombosis in BD [<xref ref-type="bibr" rid="B14">14</xref>&#x02013;<xref ref-type="bibr" rid="B19">19</xref>]. Moreover,the association between Hcy levels and endothelial dysfunction has been shownin patients with BD [<xref ref-type="bibr" rid="B20">20</xref>]. However, endothelial injury itself cannot clearlyaccount the hypercoagulable status of BD because other vasculitis syndromes donot increase the risk of thrombosis [<xref ref-type="bibr" rid="B21">21</xref>]. Additionally, existence of severalcontradictory results with respect to serum Hcy levels leads the role ofhomocysteine in BD unclear [<xref ref-type="bibr" rid="B22">22</xref>]. As vitamin B6, vitamin B12, and folic acid candecrease homocysteine levels [<xref ref-type="bibr" rid="B23">23</xref>], treatment with these vitamins can beconsidered to reduce the risk of venous and arterial thrombosis. Therefore, itis important to find a clear picture of the role of Hcy, which is thought toinduce proinflammatory cytokines [<xref ref-type="bibr" rid="B24">24</xref>] during the course of BD.</p><p>Thepresent study was conducted to evaluate serum Hcy as a serological marker forthe assessment of the activity of BD with respect to specific individual clinical manifestations. Serum levels of Hcy were compared with the values of C-reactive protein (CRP),an acute phase reactant, the erythrocyte sedimentation rate (ESR), and tumornecrosis alpha (TNF-<italic>&#x003b1;</italic>) which is an important proinflammatory cytokine. Theresults were controlled with the healthy individuals.</p><p>Inpatients with BD, the question of whether hyperhomocysteinemia depends on theinflammation has not been answered yet. Therefore, our aim was to evaluatewhether elevated Hcy levels, an independent risk factor for both venous andarterial thrombosis, associatedwith proinflammatory process mediated by cytokines in patients with BD.</p></sec><sec sec-type="section" id="sec2"><title>2. MATERIAL AND METHODS</title><sec id="sec2.1"><title>2.1. Subjects</title><p>70 patients (40 males, 30 females; mean age of 33 &#x000b1; 7.79) fulfilling the international study group criteria[<xref ref-type="bibr" rid="B25">25</xref>] for the diagnosis of BD and 33 healthy control subjects (17 males, 16females; mean age of 30 &#x000b1; 6.68) were included in this study. Patients with BDwere selected from patients who were being followed up by the departments ofdermatology and cardiovascular surgery, Behcet's Disease Unit or referred fromother departments. Subjects were newly diagnosed or patients who were nottaking any medicine regarding BD for some reason. The control subjects wereage- and sex-matched healthy hospital staff. Complete blood count, serumglucose, urea, creatinine, total cholesterol, triglyceride, uric acid, alanineaminotransferase, aspartate aminotransferease, alkaline phosphatase, vitamin B12, and folic acid levels were evaluated in all of the subjects before beingincluded into the study. Patients who had other type of illness such asautoimmune disease that could affect the cytokine levels or patients taking anymedication affecting the immune system or patients with folic acid or vitaminB12 deficiencies, diabetes mellitus, hyperlipidemia, chronic hepatitis, renalfailure, severe psoriasis, pernicious anemia, and chronic alcoholism whichmight affect Hcy levels were excluded from the study. Patients taking vitaminsupplements in the previous 6 months were also excluded from the study. Thestudy was approved by the local ethics institute. Informed consent was obtainedfrom all subjects. Pathergy test was performed and the number of activemanifestations recorded for each patient.</p></sec><sec id="sec2.2"><title>2.2. Determination of disease activity</title><p>Sinceaccepted specific clinical activity scoring system and laboratory screeningprofile for BD has not been performed so far, the activity of patients wasconsidered to have an active disease in case of the existence of two or moresymptoms with worsening of clinical symptoms and lack of wellbeing at the timeof the study. Behcet's diseaseactivity index (BDAI) was also performed on our patients according tothe method presented by Bhakta et al. [<xref ref-type="bibr" rid="B26">26</xref>] and described elaboratelyby Lawton et al. [<xref ref-type="bibr" rid="B27">27</xref>]. Anoverall disease activity scores derived from adding the scores according to theevaluation of the duration of each clinical features (from 0 to 4) and patientsand clinicians impressions of the disease activity. As it was agreed thatinclusion of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)measurements would not add significantly to overall measurement of diseaseactivity [<xref ref-type="bibr" rid="B27">27</xref>] and were not included as criteria in BDAI [<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>],ESR and CRP were not used in the determination of the activation of thedisease. The patients who had no symptoms regarding BD in four weeks period orless than two symptoms with a healing process and an overall wellbeing statuswere grouped in inactive BD.</p></sec><sec id="sec2.3"><title>2.3. Vascular examination</title><p>All patients and healthy volunteers were examined carefullyfor vascular involvement. Either venous or arterial system involvement wasdefined as present when confirmed by Doppler ultrasonography, radioisotopevenography, magnetic resonance angiography, conventional angiography, or computerizedtomography.</p></sec><sec id="sec2.4"><title>2.4. Serum homocysteine analysis</title><p>Serum homocysteine levels in the study groups were determined by fluorescencepolarization immunoassay (FPIA) technique (Axis Biochemicals, ASA, Oslo,Norway). FPIA was run on an IMx analyzer (Abbott, Ill, USA). The 95% confidence interval of plasma Hcylevel suggested by the manufacturer for healthy individuals is 4.45&#x02013;12.42 <italic>&#x003bc;</italic>mol/L andserum Hcy level is expected to be up to 10% higher than ethylenediaminetetraacetate (EDTA) plasma. Fivecc blood samples were drawn using a 25 gauge needle from a peripheralvein, avoiding haemolysis in the morning hours after an overnight fasting and30 minutes of supine rest and collected into 10 mL empty evacuated tubes withoutEDTA, heparin, or clot activators. Samples were centrifuged at 1000 &#x000d7; g for 10minutes. The serum was separated in aliquots and immediately frozen and storedat &#x02212;80&#x000b0;C within 60 minutes until use.</p></sec><sec id="sec2.5"><title>2.5. Detection of tumor necrosis alpha byenzyme-linked immunosorbant assay</title><p>The TNF-<italic>&#x003b1;</italic> level was measured with an enzyme-linked immunosorbant assay (ELISA) kit(Bender Medsystems, Vienna, Austria, Lot <italic>#</italic> 223/208-D1)with a detectable level set at 14 pg/mL. Five cc serum was separated bycentrifugation at 1000 &#x000d7; g for 10 minutes and stored at &#x02212;70&#x000b0;C until use.</p></sec><sec id="sec2.6"><title>2.6. C-reactive protein, erythrocytesedimentation rate analyses</title><p>CRP was measured by a highly sensitive turbidimetric method using conventionalbiochemical automatic analyzer. The upper limit of the normal range was 5 mg/L. The ESR was determined by the classic Westergren method.</p></sec><sec id="sec2.7"><title>2.7. Statistical analysis</title><p>Results were analyzed using SPSS for Windows VER 11.5 (SPSSInc., Chicago, Ill, USA). Each variant was evaluated by one sampleKolmogorov-Smirnov test for compatibilitywith normal distribution. As the data did not fit normal distribution, thenonparametric Kruskall-Wallis test for intergroups comparison and Mann-Whitney<italic>U</italic> test or Bonferroni corrected Mann-Whitney <italic>U</italic> tests were used for between-groupcomparisons as indicated. The relationship between variables was evaluated bySpearman correlation and regression analysis. Levels of significance set at0.05 but in Bonferroni corrected test the significance threshold of 0.05yielded to the value of 0.0167. Data are presented as median values and theirindividual ranges (in parenthesis).</p></sec></sec><sec sec-type="section" id="sec3"><title>3. RESULTS</title><p>Detected number of patients suffering from individual active clinical manifestations ofthe disease in various degrees was 31 with oral ulceration (44.28%), 23 with genital ulceration(32.85%), 18 with ocular involvement (25.71%), 37 with vascular involvement (52.85%),25 with arthritis (35.71%), and 31 with cutaneous lesions like erythema nodosum(EN) and papulopustular eruption (PPE) (44.28%). Thirty five patients (50%)were found to have positive pathergy test. According to our evaluation scale, 34patients were considered to have active disease with a median of 4 symptoms ranging between2 and 5 and 36 patients to have inactive disease with a median of 1 symptomranging between 1 and 2. Consistently, active group had a statisticallysignificant high BDAI score with a median of 16 ranging between 9 and 25compared to inactive group with a median of 2 ranging between 1 and 5 (<italic>P</italic> = .00)(<xref ref-type="table" rid="tab1">Table 1</xref>). According to vascular examination, venous involvement (deep venous thrombosiswith or without thromboflebitis) was found in 23 patients and either arterialocclusion or aneurysm was found in 14 patients in active group. 17 patients ininactive group had short duration of thromboflebitis with a wellbeing status.</p><p>In intergroupcomparison of active BD, inactive BD, and healthy controls according to serumlevels of Hcy, TNF-<italic>&#x003b1;</italic>, CRP, and ESR significant difference was detected foreach parameter (<italic>P</italic> = .00 for each parameter) (<xref ref-type="table" rid="tab1">Table 1</xref>). To determine whichgroup/groups cause the difference, between-group comparisons performed. According to this, Hcy, TNF-<italic>&#x003b1;</italic>, CRP, and ESR levels were found elevated inactive BD compared to inactive BD and healthy controls. Hcy, TNF-<italic>&#x003b1;</italic>, CRP, andESR levels of inactive BD were found elevated compared to healthy controls. Hcyand TNF-<italic>&#x003b1;</italic> suggested having a strong association of disease activity (<xref ref-type="table" rid="tab1">Table 1</xref>). Hcy and TNF-<italic>&#x003b1;</italic> were found to have high correlation with BDAI scores (<italic>r</italic> = 0.836, <italic>P</italic> = .00and <italic>r</italic> = 0.924, <italic>P</italic> = .00, resp.) and the number of active clinicalmanifestations increased (<italic>r</italic> = 0.694, <italic>P</italic> = .00 and <italic>r</italic> = 0.842, <italic>P</italic> = .00, resp.)while ESR and CRP also showed a positive correlation with both parameters withrelatively less significance (<xref ref-type="table" rid="tab2">Table 2</xref>).</p><p>The evaluation of association between specific individual clinical manifestationsand serum levels revealed increased Hcy levels in patients with oral ulcer (<italic>P</italic> = .03),genital ulcer (<italic>P</italic> = .005), the presence of positive pathergy test (<italic>P</italic> = .007),ocular lesion (<italic>P</italic> = .00), and vascular lesion of high significance (<italic>P</italic> = .00)(<xref ref-type="table" rid="tab3">Table 3</xref>). No association was foundbetween Hcy levels and EN/PPE and arthritis.</p><p>The serum levels of TNF-<italic>&#x003b1;</italic> were found to have strong association with oral ulcer (<italic>P</italic> = .00),genital ulcer (<italic>P</italic> = .00), the presence of positive pathergy test (<italic>P</italic> = .00),ocular lesion (<italic>P</italic> = .00), and vascular lesion (<italic>P</italic> = .000) (<xref ref-type="table" rid="tab4">Table 4</xref>). Noassociation was found between TNF-<italic>&#x003b1;</italic> levelsand EN/PPE and arthritis.</p><p>The association of CRP with genital ulcer (<italic>P</italic> = .001), ocular lesion (<italic>P</italic> = .001),vascular lesion (<italic>P</italic> = .001), EN/PPE (<italic>P</italic> = .043), and the presence ofpositive pathergy test (<italic>P</italic> = .016) was found. No association was found between CRP levels and ocular lesion andarthritis (<xref ref-type="table" rid="tab5">Table 5</xref>). ESR showed no significant association with any of thespecific individual clinical manifestations (<xref ref-type="table" rid="tab6">Table 6</xref>).</p><p>A significant positive correlation was found between serum Hcy and TNF-<italic>&#x003b1;</italic> levels(<italic>r</italic> = 0.89, <italic>P</italic> = .00), CRP (<italic>r</italic> = 0.645, <italic>P</italic> = .00) and ESR (<italic>r</italic> = 0.561, <italic>P</italic> = .00)(<xref ref-type="table" rid="tab2">Table 2</xref>). Among parameters, Hcy was found to be the best predictor of TNF-<italic>&#x003b1;</italic> whichwas used as a dependent variable (Beta = 6.45, <italic>R</italic><sup>2</sup> = 0.88, <italic>P</italic> = .00) (<xref ref-type="table" rid="tab7">Table 7</xref>).</p><p>Serum levels of Hcy in active BD patients with vascular involvement were foundsignificantly increased when compared in patients with active BD withoutvascular involvement. In addition, serum levels of Hcy in inactive BD withvascular involvement were found significantly increased compared to inactive BD(<xref ref-type="table" rid="tab8">Table 8</xref>).</p><p>Serum levels of active BD patients with vascular involvement, oral ulcer, arthritis/arthralgia,EN/PPE and the presence of positive pathergy test were found significantlyincreased compared to inactive BD patients with the same clinical symptoms(<xref ref-type="table" rid="tab9">Table 9</xref>).</p></sec><sec sec-type="section" id="sec4"><title>4. DISCUSSION</title><p>The mainpathology in BD is an inflammatory process of small arteries and veins andthrombosis as a result of vasculitis of the vaso vasorum [<xref ref-type="bibr" rid="B24">24</xref>]. Hyperhomocysteinemiahas been shown to be a risk factor for thrombosis in BD in some recent studies [<xref ref-type="bibr" rid="B14">14</xref>&#x02013;<xref ref-type="bibr" rid="B19">19</xref>]. In our study,serum levels of Hcy were found to have a positive correlation with BDAI scoresand total number of active clinical manifestations. We also found significantlyelevated levels of serum total Hcy in active BD when compared with inactive andcontrol groups. Ourresults supported that total serum Hcy was a reliable marker for the activityof disease [<xref ref-type="bibr" rid="B17">17</xref>]. Aksu et al. [<xref ref-type="bibr" rid="B14">14</xref>] divided their patients with BD into twogroups on the basis of thrombosis and they found hyperhomocysteinemia inpatients with a history of thrombosis. However, Leiba et al. [<xref ref-type="bibr" rid="B22">22</xref>] could notfind different serum total Hcy levels between patients with and without ahistory of thrombosis. The main limitations of this study were itsretrospective nature and the long lag period between the thrombotic events andthe time of analyses performed. Aksu et al. [<xref ref-type="bibr" rid="B14">14</xref>] evaluated their patients withrespect to current clinical activity and 10 patients were accepted asclinically active, though they could not find association between serum Hcy levelsand disease activity. The small sample size was a limitation of this study.</p><p>The main factor responsible for the increased frequency of thrombosis in BD is thoughtto be endothelial dysfunction caused by vascular inflammation [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>]. Theassociation between Hcy levels and endothelial dysfunction and its correlationto the degree of endothelial damage has been shown in patients with BD [<xref ref-type="bibr" rid="B20">20</xref>]. Hcy generates superoxide and hydrogen peroxide, bothof which have been linked to endothelial damage [<xref ref-type="bibr" rid="B15">15</xref>]. Hcy-induced vascularproblems are thoughtto be multifactorial, including direct Hcy damage to the endothelium, enhancedlipid peroxidation and increased platelet aggregation by the effects on thecoagulation system [<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B17">17</xref>].</p><p>In our study, the evaluation of association between specific individual clinicalmanifestations and serum levels revealed increased Hcy levels in patients withoral ulcer, genital ulcer, the presence of positive pathergy test andparticularly with ocular and vascular lesions of high significance. No association was found between Hcy levels and EN/PPE andarthritis. Er et al. [<xref ref-type="bibr" rid="B15">15</xref>] showed the association of Hcy levels with diseaseactivity and ocular BD. Other specific individual clinical manifestations werenot assessed in this study. Ate&#x0015f; et al. [<xref ref-type="bibr" rid="B16">16</xref>] showed the association of Hcylevels with vascular involvement in BD. However, they could not findstatistically significant difference between active and inactive diseases and associationwith mucocutaneous involvement in BD. On the other hand, Korkmaz et al. [<xref ref-type="bibr" rid="B28">28</xref>] reportedno statistically significant association between vascular involvement andhomocysteine levels, though 50% of patients with vascular involvement hadhyperhomocysteinemia. Although the mechanism is unknown, all these findingsindicate that Hcy associates with BD. However, the causes of these differentstudy outcomes are not clear. The different sample sizes, different diseasedurations or study patients under treatment that might affect outcomes mighthave contributed. In addition, the question whether hyperhomocysteinemia dependson the inflammation or not remains to be unanswered.</p><p>Although the etiopathogenesis of BD has not yet been clarified, different immunologicalabnormalities have been reported and increased spontaneous secretion of TNF-<italic>&#x003b1;</italic>,Interleukin-6 (IL-6), and Interleukin-8 (IL-8) in monocyte cultures obtainedfrom BD patients [<xref ref-type="bibr" rid="B29">29</xref>]. Necrotizing, neutrophilic (leukocytoclastic)obliterative perivasculitis, and venous thrombosis with lymphocytic andmonocytic cellular infiltration of the veins, capillaries, and the arteries ofall sizes and endothelial dysfunction are the hallmarks of BD [<xref ref-type="bibr" rid="B30">30</xref>]. Histopathologicalstudies revealed cellular infiltration consisting of lymphocytes, plasmocytes,monocytes, and peripheral polymorphonuclear leukocytes (PMNs) in varying degrees, depending on thestage of lesion in BD [<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>]. Since cytokines are involved in the regulationof functions of lymphocytes and phagocytes, they are playing important role inthe pathogenesis of the disease [<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>]. Although any organ system may beaffected, there is high prevalence of venous or arterial thrombosis in BD andmost clinical features are associated with systemic vasculitis. It has beensuggested that vasculo-Behcet disease should be classified as a neutrophilicvasculitis targeting the vasovasorum [<xref ref-type="bibr" rid="B32">32</xref>]. Aneurysm formation may be related to degeneration of arterialwall caused by inflammation of the vaso vasorum. As Hcy has profound effects concerning vascularlesions and thrombosis, vascular and ocular involvements in BD deserve specialattention. Indeed, we found significantly elevated levels of Hcy with respectto the presence of vascular involvement in the intragroup comparisons of separatelyactive and inactive BD patients.  However,in our study Hcy was found to be able to evaluate the fluctuating activity ofdisease in an objective fashion and the number of additional organ systemsaffected. This finding may imply that Hcy cannot simply be assumed to be anindependent risk factor for only vascular and ocular vaso-occlusive diseases inBD [<xref ref-type="bibr" rid="B14">14</xref>&#x02013;<xref ref-type="bibr" rid="B19">19</xref>]. That is because most clinical features are thoughtto be associated with systemic vasculitis and dermal blood vessels embolized bythrombus are observed even at the sites of needle-prick reaction [<xref ref-type="bibr" rid="B30">30</xref>]. Furthermore, endothelial injury is a characteristic finding in BD and can beobserved even in patients without any clinical vascular involvement [<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>]. These data providesinsight as to why Hcy is able to detect overall disease activitywith respect to different system involvements and why ascribed significance ofHcy is not limited only to the individual clinical manifestations of vascular orvaso-occlusive ocular involvements? Consistently, we found the association ofHcy not only  with vascular and ocular vaso-occlusivedisease but also with genital ulceration, positive pathergy test, and oralulcers in BD patients, though with less significance. Therefore, our results not only support thesuggestion that Hcy is a risk factor for vascular and ocular vaso-occlusivediseases in BD [<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>] but also identify Hcy as a risk factor for thedevelopment of most clinical features that are known to be associated withvasculitis.</p><p>We found a significant positive correlation between serum Hcy, TNF-<italic>&#x003b1;</italic> and CRP levels,and ESR with relatively less significance. Hcy was found to be the bestpredictor of TNF-<italic>&#x003b1;</italic> among other parameters. In other words, Hcy was found toexplain 88% of TNF-<italic>&#x003b1;</italic> change while CRP and ESR were found to explain 39% and 14%of TNF-<italic>&#x003b1;</italic> change, respectively. The significance of Hcy in BD represents either vascular endothelium damaged by Hcy or immune systemstimulation by Hcy, our study may demonstrate the link between Hcy andinflammation pathways in BD. That is because TNF-<italic>&#x003b1;</italic>, CRP, and ESR are indicesof inflammation. Although there are conflicting results in the literature withrespect to the reliability of ESR and CRP as markers to detectthe activity of BD and they are currently not involved as criteria in BDAIscores [<xref ref-type="bibr" rid="B27">27</xref>], CRP deserves special attention because it has a strong predictivepower of vascular events [<xref ref-type="bibr" rid="B35">35</xref>]. We found both of them were elevated in theactive stage of the disease. However, unlike CRP, ESR showed no significantassociation with any of the specific individual clinical manifestations. Relatively large sample size of our patients with vascular involvement might bea factor affecting our study outcome in favor of the significance of CRP in BD.</p><p>Chemotactic and phagocytic activitiesof neutrophils in patients with BD have been reported to be high [<xref ref-type="bibr" rid="B31">31</xref>] and TNF-<italic>&#x003b1;</italic> is a major factormodulating inflammatory responses which is known to be increased ininflammatory diseases. Recent studies showed increased TNF-<italic>&#x003b1;</italic> level in BD patients,especially in the exacerbation period [<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B30">30</xref>]. Synthesis of CRP in the liveris induced by several proinflammatory cytokines including TNF-<italic>&#x003b1;</italic>. This marks CRPas a precise objective index of inflammatory activity and surrogate ofunderlying cytokine stimulus and a sensitive marker of underlying systemicinflammation [<xref ref-type="bibr" rid="B35">35</xref>]. It has been demonstrated that coagulation indices includingfibrinogen, von Willebrand factor, and plasminogen activator activity areincreased in BD and Hcy is thought to promote the clotting cascade via severalactions including inactivation of protein C, activation of coagulation factorV, increased vascular smooth muscle cell proliferation, and inhibition ofthrombomodulin [<xref ref-type="bibr" rid="B15">15</xref>]. CRP is thought to have effects into the mechanism linkinginflammation and coagulation [<xref ref-type="bibr" rid="B35">35</xref>]. Hcy is thought to induce proinflammatorycytokines [<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B36">36</xref>&#x02013;<xref ref-type="bibr" rid="B38">38</xref>]. Invasculitis such as BD, endothelial-leukocyte interaction is an important partof the inflammation [<xref ref-type="bibr" rid="B21">21</xref>] and Hcy has been reported to increase endothelial-leukocyteinteraction [<xref ref-type="bibr" rid="B13">13</xref>]. Hcy has been shown in vivo and in vitro to promote inflammatoryprocess such as the adhesion of neutrophils to endothelial cells as well as therelease of the inflammatory cytokine IL-8 and monocyte chemoattractantprotein-1 (MPC-1) [<xref ref-type="bibr" rid="B39">39</xref>]. Hcy was shown to enhance the cytokine-stimulatedexpression of endothelial cell adhesion molecules and monocyte and T-celladhesion to endothelial cells [<xref ref-type="bibr" rid="B39">39</xref>]. Adhesion molecules are characterized not only by their abilityto cause directed migration of leukocytes into inflamed tissue, but they mayalso have biological effects on other cell types, such as endothelial cells,fibroblasts, and smooth muscle cells [<xref ref-type="bibr" rid="B40">40</xref>]. Hcy was shown to promote TNF-<italic>&#x003b1;</italic>mediated induction of vascular cell adhesion molecule-1 (VCAM-1) in endothelialcells [<xref ref-type="bibr" rid="B41">41</xref>]. With respect to innate inflammatory markers such as TNF-<italic>&#x003b1;</italic> and CRP,serum Hcy has been shown to contribute to innate immune response and to be adeterminant of TNF-<italic>&#x003b1;</italic> in hypertensive patients [<xref ref-type="bibr" rid="B36">36</xref>]. In addition, Hcy has beenshown to enhance inflammation markers in murine models [<xref ref-type="bibr" rid="B42">42</xref>]. The correlation ofHcy levels with nitric oxide has been shown in patients with BD [<xref ref-type="bibr" rid="B15">15</xref>]. Hcy isknown to increase nitric oxide production in vascular smooth muscle cells and nitricoxide is known to be released as a response to systemic immunoinflammatorydiseases [<xref ref-type="bibr" rid="B15">15</xref>]. A study demonstrated that targeting the TNF pathwaysignificantly decreased Hcy and CRP levels in patients with psoriatic arthritisand in this study, CRP showed a positive correlation with Hcy at baseline [<xref ref-type="bibr" rid="B43">43</xref>]. CRP has been shown to correlate with Hcy in BD [<xref ref-type="bibr" rid="B19">19</xref>]. Hcy has been suggested tobe related to the markers of inflammation and its elevated levels as a resultof immunosuppressive treatment [<xref ref-type="bibr" rid="B19">19</xref>]. Indeed, immunosuppressive treatments mayaffect serum levels of Hcy and TNF-<italic>&#x003b1;</italic> [<xref ref-type="bibr" rid="B44">44</xref>]. This is the reason why we studiedwith the patients who were not taking any medication regarding BD. This definiteselection decreased the number of our study population as a study limitation. In our study, serum levels of active BD patients with vascular involvement,oral ulcer, arthritis/arthralgia, EN/PPE and the presence of positive pathergytest were found significantly increased compared to inactive BD patients withthe same clinical symptoms. Therefore, serum levels of Hcy werefound to explain the wide clinical spectrum of the activity of the specificindividual symptoms.</p><p>In summary, Hcyand CRP have effects into the mechanism linking inflammation and coagulationand Hcy is thought to induce proinflammatory cytokines including TNF-<italic>&#x003b1;</italic>, whichis known to increase chemotactic and phagocytic activities of neutrophils, endothelial-leukocyteinteraction, and CRP levels. We found a high correlation between serum levelsof Hcy and TNF-<italic>&#x003b1;</italic> and Hcy was found to explain the wide clinical spectrum of theactivity of the disease and specific individual symptoms. Taking all thesefindings into account, a theory might be put forward which is open to furtherin vivo and in vitro studies; Hcy-induced inflammation may be responsible fortissue damage as well as endothelial dysfunction in BD and enhanced Hcy mayaccount for the differences observed between clinically distinct subgroups. Lowering Hcyby selected vitamin supplements or TNF blockade may be the futuredirection of prevention from developing the risk of thrombosis and vasculitisof different organ systems and thereby activation of BD disease.</p></sec><sec sec-type="section" id="sec5"><title>5. CONCLUSION</title><p>Our data identified Hcy as a risk factor for thedevelopment of not only vascular and ocular involvement but also most clinicalfeatures that are known to be associated with vasculitis in BD. In addition, serumHcy showed a strong association of disease activity and correlated with BDAIscores and the number of active clinical manifestations increased. Therefore, Hcy might be assumed as a reliablemarker for the activity of disease. Hcy was found to be the best predictor ofTNF-<italic>&#x003b1;</italic> and positively correlated with inflammatory markers. Our findingssuggest that Hcy might contribute to the pathogenesis of BD by inducinginflammation. Further investigation in clinical and experimental studies is required toconclusively demonstrate the association between Hcy and inflammatory pathways.</p></sec></body><back><ack><title>ACKNOWLEDGMENT</title><p>The authors wish to thank Banu Tabanli, Hacettepe University Faculty of Medicine,Department of Biostatistics, Ankara, Turkey, for statistical editing.</p></ack><ref-list><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McCully</surname><given-names>KS</given-names></name></person-group><article-title>Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis</article-title><source><italic>American Journal of Pathology</italic></source><year>1969</year><volume>56</volume><issue>1</issue><fpage>111</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">5792556</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harker</surname><given-names>LA</given-names></name><name><surname>Slichter</surname><given-names>SJ</given-names></name><name><surname>Scott</surname><given-names>CR</given-names></name><name><surname>Ross</surname><given-names>R</given-names></name></person-group><article-title>Homocystinemia. Vascular injury and arterial thrombosis</article-title><source><italic>The New England Journal of Medicine</italic></source><year>1974</year><volume>291</volume><issue>11</issue><fpage>537</fpage><lpage>543</lpage><pub-id pub-id-type="pmid">4212055</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harker</surname><given-names>LA</given-names></name><name><surname>Harlan</surname><given-names>JM</given-names></name><name><surname>Ross</surname><given-names>R</given-names></name></person-group><article-title>Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons</article-title><source><italic>Circulation Research</italic></source><year>1983</year><volume>53</volume><issue>6</issue><fpage>731</fpage><lpage>739</lpage><pub-id pub-id-type="pmid">6640860</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansrani</surname><given-names>M</given-names></name><name><surname>Gillespie</surname><given-names>JI</given-names></name><name><surname>Stansby</surname><given-names>G</given-names></name></person-group><article-title>Homocysteine in myointimal hyperplasia</article-title><source><italic>European Journal of Vascular and Endovascular Surgery</italic></source><year>2002</year><volume>23</volume><issue>1</issue><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">11748941</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Den Heijer</surname><given-names>M</given-names></name><name><surname>Rosendaal</surname><given-names>FR</given-names></name><name><surname>Blom</surname><given-names>HJ</given-names></name><name><surname>Gerrits</surname><given-names>WBJ</given-names></name><name><surname>Bos</surname><given-names>GMJ</given-names></name></person-group><article-title>Hyperhomocysteinemia and venous thrombosis: a meta-analysis</article-title><source><italic>Thrombosis and Haemostasis</italic></source><year>1998</year><volume>80</volume><issue>6</issue><fpage>874</fpage><lpage>877</lpage><pub-id pub-id-type="pmid">9869152</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ray</surname><given-names>JG</given-names></name></person-group><article-title>Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease</article-title><source><italic>Archives of Internal Medicine</italic></source><year>1998</year><volume>158</volume><issue>19</issue><fpage>2101</fpage><lpage>2106</lpage><pub-id pub-id-type="pmid">9801176</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wald</surname><given-names>DS</given-names></name><name><surname>Law</surname><given-names>M</given-names></name><name><surname>Morris</surname><given-names>JK</given-names></name></person-group><article-title>Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis</article-title><source><italic>British Medical Journal</italic></source><year>2002</year><volume>325</volume><issue>7374</issue><fpage>1202</fpage><lpage>1206</lpage><pub-id pub-id-type="pmid">12446535</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>R</given-names></name><name><surname>Collins</surname><given-names>R</given-names></name><name><surname>Lewington</surname><given-names>S</given-names></name><etal/></person-group><article-title>Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis</article-title><source><italic>The Journal of the American Medical Association</italic></source><year>2002</year><volume>288</volume><issue>16</issue><fpage>2015</fpage><lpage>2022</lpage></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Durand</surname><given-names>P</given-names></name><name><surname>Prost</surname><given-names>M</given-names></name><name><surname>Loreau</surname><given-names>N</given-names></name><name><surname>Lussier-Cacan</surname><given-names>S</given-names></name><name><surname>Blache</surname><given-names>D</given-names></name></person-group><article-title>Impaired homocysteine metabolism and atherothrombotic disease</article-title><source><italic>Laboratory Investigation</italic></source><year>2001</year><volume>81</volume><issue>5</issue><fpage>645</fpage><lpage>672</lpage><pub-id pub-id-type="pmid">11351038</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hankey</surname><given-names>GJ</given-names></name><name><surname>Eikelboom</surname><given-names>JW</given-names></name></person-group><article-title>Homocysteine and vascular disease</article-title><source><italic>The Lancet</italic></source><year>1999</year><volume>354</volume><issue>9176</issue><fpage>407</fpage><lpage>413</lpage></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Behcet</surname><given-names>H</given-names></name></person-group><article-title>&#x000dc;ber rezidivierende, apht&#x000f6;se, durch ein virus verursachte Geshw&#x000fc;re am Mund am Auge und an den Genitalien</article-title><source><italic>Dermatol Wochensch</italic></source><year>1937</year><volume>105</volume><fpage>1152</fpage><lpage>1157</lpage></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koc</surname><given-names>Y</given-names></name><name><surname>G&#x000fc;ll&#x000fc;</surname><given-names>I</given-names></name><name><surname>Akpek</surname><given-names>G</given-names></name><etal/></person-group><article-title>Vascular involvement in Beh&#x000e7;et's disease</article-title><source><italic>Journal of Rheumatology</italic></source><year>1992</year><volume>19</volume><issue>3</issue><fpage>402</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">1578454</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dudman</surname><given-names>NPB</given-names></name><name><surname>Temple</surname><given-names>SE</given-names></name><name><surname>Guo</surname><given-names>XW</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Perry</surname><given-names>MA</given-names></name></person-group><article-title>Homocysteine enhances neutrophil-endothelial interactions in both cultured human cells and rats in vivo</article-title><source><italic>Circulation Research</italic></source><year>1999</year><volume>84</volume><issue>4</issue><fpage>409</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">10066675</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aksu</surname><given-names>K</given-names></name><name><surname>Turgan</surname><given-names>N</given-names></name><name><surname>Oksel</surname><given-names>F</given-names></name><etal/></person-group><article-title>Hyperhomocysteinaemia in Beh&#x000e7;et's disease</article-title><source><italic>Rheumatology</italic></source><year>2001</year><volume>40</volume><issue>6</issue><fpage>687</fpage><lpage>690</lpage><pub-id pub-id-type="pmid">11426028</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Er</surname><given-names>H</given-names></name><name><surname>Evereklioglu</surname><given-names>C</given-names></name><name><surname>Cumurcu</surname><given-names>T</given-names></name><etal/></person-group><article-title>Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Beh&#x000e7;et's disease</article-title><source><italic>British Journal of Ophthalmology</italic></source><year>2002</year><volume>86</volume><issue>6</issue><fpage>653</fpage><lpage>657</lpage><pub-id pub-id-type="pmid">12034688</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ate&#x0015f;</surname><given-names>A</given-names></name><name><surname>Ayd&#x00131;ntu&#x0011f;</surname><given-names>O</given-names></name><name><surname>&#x000d6;lmez</surname><given-names>U</given-names></name><name><surname>D&#x000fc;zg&#x000fc;n</surname><given-names>N</given-names></name><name><surname>Duman</surname><given-names>M</given-names></name></person-group><article-title>Serum homocysteine level is higher in Beh&#x000e7;et's disease with vascular involvement</article-title><source><italic>Rheumatology International</italic></source><year>2005</year><volume>25</volume><issue>1</issue><fpage>42</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">14586553</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sarican</surname><given-names>T</given-names></name><name><surname>Ayabakan</surname><given-names>H</given-names></name><name><surname>Turkmen</surname><given-names>S</given-names></name><name><surname>Kalaslioglu</surname><given-names>V</given-names></name><name><surname>Baran</surname><given-names>F</given-names></name><name><surname>Yenice</surname><given-names>N</given-names></name></person-group><article-title>Homocysteine: an activity marker in Beh&#x000e7;et's disease?</article-title><source><italic>Journal of Dermatological Science</italic></source><year>2007</year><volume>45</volume><issue>2</issue><fpage>121</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">17182219</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>&#x000d6;zkan</surname><given-names>Y</given-names></name><name><surname>Yard&#x00131;m-Akayd&#x00131;n</surname><given-names>S</given-names></name><name><surname>Sepici</surname><given-names>A</given-names></name><name><surname>Engin</surname><given-names>B</given-names></name><name><surname>Sepici</surname><given-names>V</given-names></name><name><surname>&#x0015e;im&#x0015f;ek</surname><given-names>B</given-names></name></person-group><article-title>Assessment of homocysteine, neopterin and nitric oxide levels in Beh&#x000e7;et's disease</article-title><source><italic>Clinical Chemistry and Laboratory Medicine</italic></source><year>2007</year><volume>45</volume><issue>1</issue><fpage>73</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">17243919</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yesilova</surname><given-names>Z</given-names></name><name><surname>Pay</surname><given-names>S</given-names></name><name><surname>Oktenli</surname><given-names>C</given-names></name><etal/></person-group><article-title>Hyperhomocysteinemia in patients with Beh&#x000e7;et's disease: is it due to inflammation or therapy?</article-title><source><italic>Rheumatology International</italic></source><year>2005</year><volume>25</volume><issue>6</issue><fpage>423</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">15057566</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ozdemir</surname><given-names>R</given-names></name><name><surname>Barutcu</surname><given-names>I</given-names></name><name><surname>Sezgin</surname><given-names>AT</given-names></name><etal/></person-group><article-title>Vascular endothelial function and plasma homocysteine levels in Beh&#x000e7;et's disease</article-title><source><italic>The American Journal of Cardiology</italic></source><year>2004</year><volume>94</volume><issue>4</issue><fpage>522</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">15325946</pub-id></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Kang</surname><given-names>SW</given-names></name><name><surname>Yang</surname><given-names>JI</given-names></name><etal/></person-group><article-title>Coagulation parameters and plasma total homocysteine levels in Beh&#x000e7;et's disease</article-title><source><italic>Thrombosis Research</italic></source><year>2002</year><volume>106</volume><issue>1</issue><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">12165284</pub-id></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leiba</surname><given-names>M</given-names></name><name><surname>Seligsohn</surname><given-names>U</given-names></name><name><surname>Sidi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Thrombophilic factors are not the leading cause of thrombosis in Beh&#x000e7;et's disease</article-title><source><italic>Annals of the Rheumatic Diseases</italic></source><year>2004</year><volume>63</volume><issue>11</issue><fpage>1445</fpage><lpage>1449</lpage><pub-id pub-id-type="pmid">15479893</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Selhub</surname><given-names>J</given-names></name><name><surname>Jacques</surname><given-names>PF</given-names></name><name><surname>Wilson</surname><given-names>PW</given-names></name><name><surname>Rush</surname><given-names>D</given-names></name><name><surname>Rosenberg</surname><given-names>IH</given-names></name></person-group><article-title>Vitamin status and intake as primary determinants of homocysteinemia in an elderly population</article-title><source><italic>The Journal of the American Medical Association</italic></source><year>1993</year><volume>270</volume><issue>22</issue><fpage>2693</fpage><lpage>2698</lpage></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evereklioglu</surname><given-names>C</given-names></name><name><surname>Er</surname><given-names>H</given-names></name><name><surname>T&#x000fc;rk&#x000f6;z</surname><given-names>Y</given-names></name><name><surname>&#x000c7;ekmen</surname><given-names>M</given-names></name></person-group><article-title>Serum levels of TNF-<italic>&#x003b1;</italic>, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Beh&#x000e7;et's disease</article-title><source><italic>Mediators of Inflammation</italic></source><year>2002</year><volume>11</volume><issue>2</issue><fpage>87</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">12061429</pub-id></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wechsler</surname><given-names>B</given-names></name><name><surname>Davatchi</surname><given-names>F</given-names></name><name><surname>Mizushima</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Criteria for diagnosis of Beh&#x000e7;et's disease</article-title><source><italic>The Lancet</italic></source><year>1990</year><volume>335</volume><issue>8697</issue><fpage>1078</fpage><lpage>1080</lpage></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bhakta</surname><given-names>BB</given-names></name><name><surname>Brennan</surname><given-names>P</given-names></name><name><surname>James</surname><given-names>TE</given-names></name><name><surname>Chamberlain</surname><given-names>MA</given-names></name><name><surname>Noble</surname><given-names>BA</given-names></name><name><surname>Silman</surname><given-names>AJ</given-names></name></person-group><article-title>Beh&#x000e7;et's disease: evaluation of a new instrument to measure clinical activity</article-title><source><italic>Rheumatology</italic></source><year>1999</year><volume>38</volume><issue>8</issue><fpage>728</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">10501420</pub-id></citation></ref><ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lawton</surname><given-names>G</given-names></name><name><surname>Bhakta</surname><given-names>BB</given-names></name><name><surname>Chamberlain</surname><given-names>MA</given-names></name><name><surname>Tennant</surname><given-names>A</given-names></name></person-group><article-title>The Beh&#x000e7;et's disease activity index</article-title><source><italic>Rheumatology</italic></source><year>2004</year><volume>43</volume><issue>1</issue><fpage>73</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">12890862</pub-id></citation></ref><ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Korkmaz</surname><given-names>C</given-names></name><name><surname>Bozan</surname><given-names>B</given-names></name><name><surname>Kosar</surname><given-names>M</given-names></name><name><surname>Sahin</surname><given-names>F</given-names></name><name><surname>G&#x000fc;lbas</surname><given-names>Z</given-names></name></person-group><article-title>Is there an association of plasma homocysteine levels with vascular involvement in patients with Beh&#x000e7;et's syndrome?</article-title><source><italic>Clinical and Experimental Rheumatology</italic></source><year>2002</year><volume>20</volume><issue>4</issue><supplement>supplement 26</supplement><fpage>S30</fpage><lpage>S34</lpage><pub-id pub-id-type="pmid">12371632</pub-id></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mege</surname><given-names>J-L</given-names></name><name><surname>Dilsen</surname><given-names>N</given-names></name><name><surname>Sanguedolce</surname><given-names>V</given-names></name><etal/></person-group><article-title>Over production of monocyte derived tumor necrosis factor <italic>&#x003b1;</italic>, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Beh&#x000e7;et's disease. A comparative study with familial Mediterranean fever and healthy subjects</article-title><source><italic>Journal of Rheumatology</italic></source><year>1993</year><volume>20</volume><issue>9</issue><fpage>1544</fpage><lpage>1549</lpage><pub-id pub-id-type="pmid">8164212</pub-id></citation></ref><ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evereklioglu</surname><given-names>C</given-names></name></person-group><article-title>Current concepts in the etiology and treatment of Beh&#x000e7;et disease</article-title><source><italic>Survey of Ophthalmology</italic></source><year>2005</year><volume>50</volume><issue>4</issue><fpage>297</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">15967189</pub-id></citation></ref><ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baggiolini</surname><given-names>M</given-names></name><name><surname>Dewald</surname><given-names>B</given-names></name><name><surname>Moser</surname><given-names>B</given-names></name></person-group><article-title>Human chemokines: an update</article-title><source><italic>Annual Review of Immunology</italic></source><year>1997</year><volume>15</volume><fpage>675</fpage><lpage>705</lpage></citation></ref><ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>M</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Nakagawa</surname><given-names>A</given-names></name><etal/></person-group><article-title>Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Beh&#x000e7;et disease</article-title><source><italic>Histopathology</italic></source><year>2000</year><volume>36</volume><issue>4</issue><fpage>362</fpage><lpage>371</lpage><pub-id pub-id-type="pmid">10759951</pub-id></citation></ref><ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haznedaroglu</surname><given-names>IC</given-names></name><name><surname>Ozdemir</surname><given-names>O</given-names></name><name><surname>Ozcebe</surname><given-names>O</given-names></name><name><surname>Dundar</surname><given-names>SV</given-names></name><name><surname>Kirazli</surname><given-names>S</given-names></name></person-group><article-title>Circulating thrombomodulin as a clue of endothelial damage in Beh&#x000e7;et's disease</article-title><source><italic>Thrombosis and Haemostasis</italic></source><year>1996</year><volume>75</volume><issue>6</issue><fpage>974</fpage><lpage>975</lpage><pub-id pub-id-type="pmid">8822597</pub-id></citation></ref><ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haznedaroglu</surname><given-names>IC</given-names></name><name><surname>&#x000d6;zcebe</surname><given-names>OI</given-names></name><name><surname>&#x000d6;zdemir</surname><given-names>O</given-names></name><name><surname>&#x000c7;elik</surname><given-names>I</given-names></name><name><surname>D&#x000fc;ndar</surname><given-names>SV</given-names></name><name><surname>Kirazli</surname><given-names>&#x0015e;</given-names></name></person-group><article-title>Impaired haemostatic kinetics and endothelial function in Beh&#x000e7;et's disease</article-title><source><italic>Journal of Internal Medicine</italic></source><year>1996</year><volume>240</volume><issue>4</issue><fpage>181</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">8918508</pub-id></citation></ref><ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohkuma</surname><given-names>T</given-names></name><name><surname>Minagawa</surname><given-names>T</given-names></name><name><surname>Takada</surname><given-names>N</given-names></name><name><surname>Ohno</surname><given-names>M</given-names></name><name><surname>Oda</surname><given-names>H</given-names></name><name><surname>Ohashi</surname><given-names>H</given-names></name></person-group><article-title>C-reactive protein, lipoprotein(a), homocysteine, and male sex contribute to carotid atherosclerosis in peritoneal dialysis patients</article-title><source><italic>American Journal of Kidney Diseases</italic></source><year>2003</year><volume>42</volume><issue>2</issue><fpage>355</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">12900819</pub-id></citation></ref><ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bogdanski</surname><given-names>P</given-names></name><name><surname>Pupek-Musialik</surname><given-names>D</given-names></name><name><surname>Dytfeld</surname><given-names>J</given-names></name><name><surname>Lacinski</surname><given-names>M</given-names></name><name><surname>Jablecka</surname><given-names>A</given-names></name><name><surname>Jakubowski</surname><given-names>H</given-names></name></person-group><article-title>Plasma homocysteine is a determinant of tissue necrosis factor-<italic>&#x003b1;</italic> in hypertensive patients</article-title><source><italic>Biomedicine and Pharmacotherapy</italic></source><year>2008</year><volume>62</volume><issue>6</issue><fpage>360</fpage><lpage>365</lpage></citation></ref><ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gori</surname><given-names>AM</given-names></name><name><surname>Corsi</surname><given-names>AM</given-names></name><name><surname>Fedi</surname><given-names>S</given-names></name><etal/></person-group><article-title>A proinflammatory state is associated with hyperhomocysteinemia in the elderly</article-title><source><italic>American Journal of Clinical Nutrition</italic></source><year>2005</year><volume>82</volume><issue>2</issue><fpage>335</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">16087976</pub-id></citation></ref><ref id="B38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Widner</surname><given-names>B</given-names></name><name><surname>Leblhuber</surname><given-names>F</given-names></name><name><surname>Frick</surname><given-names>B</given-names></name><name><surname>Laich</surname><given-names>A</given-names></name><name><surname>Artner-Dworzak</surname><given-names>E</given-names></name><name><surname>Fuchs</surname><given-names>D</given-names></name></person-group><article-title>Moderate hyperhomocysteinaemia and immune activation in Parkinson's disease</article-title><source><italic>Journal of Neural Transmission</italic></source><year>2002</year><volume>109</volume><issue>12</issue><fpage>1445</fpage><lpage>1452</lpage><pub-id pub-id-type="pmid">12486485</pub-id></citation></ref><ref id="B39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koga</surname><given-names>T</given-names></name><name><surname>Claycombe</surname><given-names>K</given-names></name><name><surname>Meydani</surname><given-names>M</given-names></name></person-group><article-title>Homocysteine increases monocyte and T-cell adhesion to human aortic endothelial cells</article-title><source><italic>Atherosclerosis</italic></source><year>2002</year><volume>161</volume><issue>2</issue><fpage>365</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">11888519</pub-id></citation></ref><ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y-S</given-names></name><name><surname>Feng</surname><given-names>Y-B</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>C-Z</given-names></name></person-group><article-title>Folic acid reduces adhesion molecules VCAM-1 expession in aortic of rats with hyperhomocysteinemia</article-title><source><italic>International Journal of Cardiology</italic></source><year>2006</year><volume>106</volume><issue>2</issue><fpage>285</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">16183151</pub-id></citation></ref><ref id="B41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>MD</given-names></name><name><surname>Tumuluri</surname><given-names>RJ</given-names></name><name><surname>Davis</surname><given-names>M</given-names></name><name><surname>Lopez</surname><given-names>G</given-names></name><name><surname>Rosenbaum</surname><given-names>JT</given-names></name><name><surname>Lelkes</surname><given-names>PI</given-names></name></person-group><article-title>Homocysteine upregulates vascular cell adhesion molecule-1 expression in cultured human aortic endothelial cells and enhances monocyte adhesion</article-title><source><italic>Arteriosclerosis, Thrombosis, and Vascular Biology</italic></source><year>2002</year><volume>22</volume><issue>4</issue><fpage>587</fpage><lpage>592</lpage></citation></ref><ref id="B42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hofmann</surname><given-names>MA</given-names></name><name><surname>Lalla</surname><given-names>E</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model</article-title><source><italic>The Journal of Clinical Investigation</italic></source><year>2001</year><volume>107</volume><issue>6</issue><fpage>675</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">11254667</pub-id></citation></ref><ref id="B43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sattar</surname><given-names>N</given-names></name><name><surname>Crompton</surname><given-names>P</given-names></name><name><surname>Cherry</surname><given-names>L</given-names></name><name><surname>Kane</surname><given-names>D</given-names></name><name><surname>Lowe</surname><given-names>G</given-names></name><name><surname>McInnes</surname><given-names>IB</given-names></name></person-group><article-title>Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study</article-title><source><italic>Arthritis &#x00026; Rheumatism</italic></source><year>2007</year><volume>56</volume><issue>3</issue><fpage>831</fpage><lpage>839</lpage><pub-id pub-id-type="pmid">17328057</pub-id></citation></ref><ref id="B44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ballow</surname><given-names>M</given-names></name><name><surname>Nelson</surname><given-names>R</given-names></name></person-group><article-title>Immunopharmacology: immunomodulation and immunotherapy</article-title><source><italic>The Journal of the American Medical Association</italic></source><year>1997</year><volume>278</volume><issue>22</issue><fpage>2008</fpage><lpage>2017</lpage></citation></ref></ref-list></back><floats-wrap><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Comparision of serum homocysteine, TNF-<italic>&#x003b1;</italic>,CRP, and ESR values and BDAI scores between groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Homocysteine (<italic>&#x003bc;</italic>mol/L)</th><th align="center" rowspan="1" colspan="1">TNF-<italic>&#x003b1;</italic> (pg/mL)</th><th align="center" rowspan="1" colspan="1">ESR (mm/h)</th><th align="center" rowspan="1" colspan="1">CRP (mg/L)</th><th align="center" rowspan="1" colspan="1">BDAI scores</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" colspan="5" rowspan="1">Median (range)</td></tr><tr><td align="center" colspan="7" rowspan="1"><hr/></td></tr><tr><td align="left" colspan="2" rowspan="1">Group I (active BD) (<italic>n</italic> = 34)</td><td align="center" rowspan="1" colspan="1">20.95 (13.7&#x02013;39.25)</td><td align="center" rowspan="1" colspan="1">93.5 (30&#x02013;228)</td><td align="center" rowspan="1" colspan="1">24 (2&#x02013;95)</td><td align="center" rowspan="1" colspan="1">20.5 (3&#x02013;400)</td><td align="center" rowspan="1" colspan="1">16 (9&#x02013;25)</td></tr><tr><td align="left" colspan="2" rowspan="1">Group II (inactive BD) (<italic>n</italic> = 36)</td><td align="center" rowspan="1" colspan="1">13 (6.43&#x02013;18)</td><td align="center" rowspan="1" colspan="1">19 (15&#x02013;30)</td><td align="center" rowspan="1" colspan="1">27 (8&#x02013;49)</td><td align="center" rowspan="1" colspan="1">6.65 (3&#x02013;34)</td><td align="center" rowspan="1" colspan="1">2 (1&#x02013;5)</td></tr><tr><td align="left" colspan="2" rowspan="1">Group III (healthy control) (<italic>n</italic> = 33)</td><td align="center" rowspan="1" colspan="1">8 (5&#x02013;8)</td><td align="center" rowspan="1" colspan="1">0 (0&#x02013;18)</td><td align="center" rowspan="1" colspan="1">6 (2&#x02013;18)</td><td align="center" rowspan="1" colspan="1">3.1 (3&#x02013;10)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="7" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="4" colspan="1"> Significance for groups</td><td align="center" rowspan="1" colspan="1">I-II-III</td><td align="center" rowspan="1" colspan="1"><sup>a</sup><italic>P</italic> = .00*</td><td align="center" rowspan="1" colspan="1"><sup>a</sup><italic>P</italic> = .00*</td><td align="center" rowspan="1" colspan="1"><sup>a</sup><italic>P</italic> = .00*</td><td align="center" rowspan="1" colspan="1"><sup>a</sup><italic>P</italic> = .00*</td><td align="center" rowspan="4" colspan="1"><sup>c</sup><italic>P</italic> = .00*</td></tr><tr><td align="center" rowspan="1" colspan="1">I-II</td><td align="center" rowspan="1" colspan="1"><sup>b</sup><italic>P</italic> = .00*</td><td align="center" rowspan="1" colspan="1"><sup>b</sup><italic>P</italic> = .00*</td><td align="center" rowspan="1" colspan="1"><sup>b</sup><italic>P</italic> = .001*</td><td align="center" rowspan="1" colspan="1"><sup>b</sup><italic>P</italic> = .00*</td></tr><tr><td align="center" rowspan="1" colspan="1">I-III</td><td align="center" rowspan="1" colspan="1"><sup>b</sup><italic>P</italic> = .00*</td><td align="center" rowspan="1" colspan="1"><sup>b</sup><italic>P</italic> = .00*</td><td align="center" rowspan="1" colspan="1"><sup>b</sup><italic>P</italic> = .00*</td><td align="center" rowspan="1" colspan="1"><sup>b</sup><italic>P</italic> = .00*</td></tr><tr><td align="center" rowspan="1" colspan="1">II-III</td><td align="center" rowspan="1" colspan="1"><sup>b</sup><italic>P</italic> = .00*</td><td align="center" rowspan="1" colspan="1"><sup>b</sup><italic>P</italic> = .00*</td><td align="center" rowspan="1" colspan="1"><sup>b</sup><italic>P</italic> = .008*</td><td align="center" rowspan="1" colspan="1"><sup>b</sup><italic>P</italic> = .00*</td></tr></tbody></table><table-wrap-foot><fn><p>						<sup>a</sup><italic>P</italic>* Significantly different by Kruskal-Wallistest (<italic>P</italic> &#x0003c; .05).</p><p>						<sup>b</sup><italic>P</italic>* Significantly different by Bonferronicorrected Mann-Withney <italic>U</italic> test  (<italic>P</italic> &#x0003c; .0167).</p><p>						<sup>c</sup><italic>P</italic>* Significantly different by Mann-Withney <italic>U</italic> test (<italic>P</italic> &#x0003c; .05).</p><p>Data are presented  asmedian values and their individual ranges within parentheses.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" position="float"><label>Table 2</label><caption><p>The relationship between variables.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Hcy</th><th align="center" rowspan="1" colspan="1">ESR</th><th align="center" rowspan="1" colspan="1">CRP</th><th align="center" rowspan="1" colspan="1">TNF</th><th align="center" rowspan="1" colspan="1">Total&#x02020;</th><th align="center" rowspan="1" colspan="1">BDAI</th></tr></thead><tbody><tr><td align="center" colspan="7" rowspan="1">Spearman correlation coefficient and <italic>P</italic>-values</td></tr><tr><td align="center" colspan="7" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="2" colspan="1">Hcy</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.561</td><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.645</td><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.889  </td><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.694</td><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.836</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td></tr><tr><td align="center" colspan="7" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="2" colspan="1">ESR</td><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.561</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.421</td><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.538  </td><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.304</td><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.408</td></tr><tr><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .011</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td></tr><tr><td align="center" colspan="7" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="2" colspan="1">CRP</td><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.645</td><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.421</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.670  </td><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.549</td><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.583</td></tr><tr><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td></tr><tr><td align="center" colspan="7" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="2" colspan="1">TNF</td><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.889</td><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.538</td><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.670 </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.842  </td><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.924</td></tr><tr><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td></tr><tr><td align="center" colspan="7" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="2" colspan="1">Total&#x02020;</td><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.694 </td><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.304</td><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.549 </td><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.842 </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.842</td></tr><tr><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .011</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td></tr><tr><td align="center" colspan="7" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="2" colspan="1">BDAI</td><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.836</td><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.408</td><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.583 </td><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.924 </td><td align="center" rowspan="1" colspan="1"><italic>r</italic> =  0.842</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>Total&#x02020; number of active clinical manifestations for each patient.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab3" position="float"><label>Table 3</label><caption><p>The significance of the association of Hcy with versus without individualclinical manifestations and pathergy reaction.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Hcy levels (<italic>&#x003bc;</italic>mol/L) in patients with</th><th align="center" colspan="2" rowspan="1">Hcy levels (<italic>&#x003bc;</italic>mol/L) in patients without</th><th align="center" rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1">Manifestations</th><th align="center" rowspan="1" colspan="1">No. of Patients</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">(Range)</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">(Range)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-values</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Oral ulcer</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">18.03</td><td align="center" rowspan="1" colspan="1">(8&#x02013;39.3)</td><td align="center" rowspan="1" colspan="1">14.28</td><td align="center" rowspan="1" colspan="1">(6.4&#x02013;29)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .003*</td></tr><tr><td align="left" rowspan="1" colspan="1">Genital ulcer</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">18.1</td><td align="center" rowspan="1" colspan="1">(11.9&#x02013;38.1)</td><td align="center" rowspan="1" colspan="1">14.28</td><td align="center" rowspan="1" colspan="1">(6.4&#x02013;39.3)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .005*</td></tr><tr><td align="left" rowspan="1" colspan="1">Ocular lesion</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">21.59</td><td align="center" rowspan="1" colspan="1">(14&#x02013;39.3)</td><td align="center" rowspan="1" colspan="1">14.15</td><td align="center" rowspan="1" colspan="1">(6.4&#x02013;38)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00*</td></tr><tr><td align="left" rowspan="1" colspan="1">Vascular lesion</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">(11.9&#x02013;39.3)</td><td align="center" rowspan="1" colspan="1">13.75</td><td align="center" rowspan="1" colspan="1">(6.4&#x02013;26)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00*</td></tr><tr><td align="left" rowspan="1" colspan="1">Arthritis/arthralgia</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">(6.4&#x02013;39.3)</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">(8&#x02013;38.1)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .99</td></tr><tr><td align="left" rowspan="1" colspan="1">EN/PPE</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">(8.1&#x02013;38.1)</td><td align="center" rowspan="1" colspan="1">14.88</td><td align="center" rowspan="1" colspan="1">(6.4&#x02013;39.3)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .306</td></tr><tr><td align="left" rowspan="1" colspan="1">(+) pathergy</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">17.2</td><td align="center" rowspan="1" colspan="1">(7.9&#x02013;38.1)</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">(6.4&#x02013;39.3)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .007*</td></tr></tbody></table><table-wrap-foot><fn><p>						<italic>P</italic>* &#x0003c; .05 by Mann-Whitney <italic>U</italic> test (statisticallysignificant with versus without clinical manifestations).</p><p>Data are presented  as median values and their individual ranges within  parentheses.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab4" position="float"><label>Table 4</label><caption><p>The significance of the association of TNF-<italic>&#x003b1;</italic> with versus without individualclinical manifestations and pathergy reaction.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">TNF-<italic>&#x003b1;</italic> levels (pg/mL) in patients with</th><th align="center" colspan="2" rowspan="1">TNF-<italic>&#x003b1;</italic> levels (pg/mL) in patients without</th><th align="center" rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1">Manifestations</th><th align="center" rowspan="1" colspan="1">No. of patients</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">(Range)</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">(Range)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-values</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Oral ulcer</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">(15&#x02013;228)</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">(15&#x02013;150)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00*</td></tr><tr><td align="left" rowspan="1" colspan="1">Genital ulcer</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">(17&#x02013;228)</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">(15&#x02013;228)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00*</td></tr><tr><td align="left" rowspan="1" colspan="1">Ocular lesion</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">(30&#x02013;228)</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">(15&#x02013;180)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00*</td></tr><tr><td align="left" rowspan="1" colspan="1">Vascular lesion</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">84</td><td align="center" rowspan="1" colspan="1">(15&#x02013;228)</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">(15&#x02013;145)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00*</td></tr><tr><td align="left" rowspan="1" colspan="1">Arthritis/arthralgia</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">(15&#x02013;228)</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">(15&#x02013;228)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .49</td></tr><tr><td align="left" rowspan="1" colspan="1">EN/PPE</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">(15&#x02013;228)</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">(15&#x02013;228)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .086</td></tr><tr><td align="left" rowspan="1" colspan="1">(+) pathergy</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">(15&#x02013;228)</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">(15&#x02013;228)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00*</td></tr></tbody></table><table-wrap-foot><fn><p>						<italic>P</italic>* &#x0003c; .05 by Mann-Whitney <italic>U</italic> test (statisticallysignificant with versus without clinical manifestations).</p><p>Data are presented  asmedian values and their individual ranges within  parentheses.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab5" position="float"><label>Table 5</label><caption><p>The significance of the association of CRP with versus without individualclinical manifestations and pathergy reaction.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">CRP levels (mg/L) in patients with</th><th align="center" colspan="2" rowspan="1">CRP levels (mg/L) in patients without</th><th align="center" rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1">Manifestations</th><th align="center" rowspan="1" colspan="1">No. of patients</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">(Range)</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">(Range)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-values</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Oral ulcer</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">12.4</td><td align="center" rowspan="1" colspan="1">(3&#x02013;400)</td><td align="center" rowspan="1" colspan="1">8.7</td><td align="center" rowspan="1" colspan="1">(3&#x02013;43)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .159</td></tr><tr><td align="left" rowspan="1" colspan="1">Genital ulcer</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">(3&#x02013;100)</td><td align="center" rowspan="1" colspan="1">8.4</td><td align="center" rowspan="1" colspan="1">(3&#x02013;400)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .001*</td></tr><tr><td align="left" rowspan="1" colspan="1">Ocular lesion</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">19.25</td><td align="center" rowspan="1" colspan="1">(3&#x02013;400)</td><td align="center" rowspan="1" colspan="1">8.5</td><td align="center" rowspan="1" colspan="1">(3&#x02013;68)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .001*</td></tr><tr><td align="left" rowspan="1" colspan="1">Vascular lesion</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">20.5</td><td align="center" rowspan="1" colspan="1">(3&#x02013;400)</td><td align="center" rowspan="1" colspan="1">8.4</td><td align="center" rowspan="1" colspan="1">(3&#x02013;51)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .001*</td></tr><tr><td align="left" rowspan="1" colspan="1">Arthritis/arthralgia</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">8.4</td><td align="center" rowspan="1" colspan="1">(3&#x02013;400)</td><td align="center" rowspan="1" colspan="1">12.9</td><td align="center" rowspan="1" colspan="1">(3&#x02013;400)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .201</td></tr><tr><td align="left" rowspan="1" colspan="1">EN/PPE</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">12.9</td><td align="center" rowspan="1" colspan="1">(3&#x02013;400)</td><td align="center" rowspan="1" colspan="1">8.9</td><td align="center" rowspan="1" colspan="1">(3&#x02013;400)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .043*</td></tr><tr><td align="left" rowspan="1" colspan="1">(+) pathergy</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">14.8</td><td align="center" rowspan="1" colspan="1">(3&#x02013;400)</td><td align="center" rowspan="1" colspan="1">8.7</td><td align="center" rowspan="1" colspan="1">(3&#x02013;400)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .016*</td></tr></tbody></table><table-wrap-foot><fn><p>						<italic>P</italic>* &#x0003c; .05 by Mann-Whitney <italic>U</italic> test (statisticallysignificant with versus without clinical manifestations).</p><p>Data are presented as median values and their individualranges within  parentheses.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab6" position="float"><label>Table 6</label><caption><p>The significance of the association of ESR with versus without individualclinical manifestations and pathergy reaction.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">ESR levels (mm/h) in patients with</th><th align="center" colspan="2" rowspan="1">ESR levels (mm/h) in patients without</th><th align="center" rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1">Manifestations</th><th align="center" rowspan="1" colspan="1">No. of patients</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">(Range)</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">(Range)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-values</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Oral ulcer</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">(2&#x02013;95)</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">(2&#x02013;70)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .113</td></tr><tr><td align="left" rowspan="1" colspan="1">Genital ulcer</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">(2&#x02013;95)</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">(2&#x02013;60)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .121</td></tr><tr><td align="left" rowspan="1" colspan="1">Ocular lesion</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">(2&#x02013;86)</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">(2&#x02013;95)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .291</td></tr><tr><td align="left" rowspan="1" colspan="1">Vascular lesion</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">(2&#x02013;70)</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">(2&#x02013;95)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .642</td></tr><tr><td align="left" rowspan="1" colspan="1">Arthritis/arthralgia</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">(3&#x02013;60)</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">(2&#x02013;95)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .317</td></tr><tr><td align="left" rowspan="1" colspan="1">EN/PPE</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">(2&#x02013;95)</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">(2&#x02013;70)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .070</td></tr><tr><td align="left" rowspan="1" colspan="1">(+) pathergy</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">(2&#x02013;95)</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">(3&#x02013;49)</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .173</td></tr></tbody></table><table-wrap-foot><fn><p>						<italic>P</italic>* &#x0003c; .05by Mann-Whitney <italic>U</italic> test (statistically significant with versus without clinicalmanifestations).</p><p>Data are presented  asmedian values and their individual ranges within  parentheses.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab7" position="float"><label>Table 7</label><caption><p>Predictors of plasma TNF-<italic>&#x003b1;</italic> level: regression analysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Predictor of TNF-<italic>&#x003b1;</italic></th><th align="center" rowspan="1" colspan="1"><italic>R</italic><sup>2</sup></th><th align="center" rowspan="1" colspan="1">Beta</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Hcy</td><td align="center" rowspan="1" colspan="1">0.88</td><td align="center" rowspan="1" colspan="1">6.45</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td></tr><tr><td align="left" rowspan="1" colspan="1">CRP</td><td align="center" rowspan="1" colspan="1">0.39</td><td align="center" rowspan="1" colspan="1">0.559</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td></tr><tr><td align="left" rowspan="1" colspan="1">ESR</td><td align="center" rowspan="1" colspan="1">0.146</td><td align="center" rowspan="1" colspan="1">1.15</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = .00</td></tr></tbody></table><table-wrap-foot><fn><p>Dependent variable: TNF-<italic>&#x003b1;</italic>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab8" position="float"><label>Table 8</label><caption><p>Comparison of Hcy intragroups of active and inactive patients according to presence ofvascular involvement.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="3" rowspan="1">Hcy levels (<italic>&#x003bc;</italic>mol/L)</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">Range</th><th align="center" rowspan="1" colspan="1"><italic>P-</italic> values</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Active BD (<italic>n</italic> = 34)</td><td align="left" rowspan="1" colspan="1">With vascular involvement (<italic>n</italic> = 20)</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">19&#x02013;39.25</td><td align="center" rowspan="2" colspan="1">.00*</td></tr><tr><td align="left" rowspan="1" colspan="1">Without vascular involvement (<italic>n</italic> = 14)</td><td align="center" rowspan="1" colspan="1">15.98</td><td align="center" rowspan="1" colspan="1">13.7&#x02013;26</td></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="2" colspan="1">Inactive BD (<italic>n</italic> = 36)</td><td align="left" rowspan="1" colspan="1">With vascular involvement (<italic>n</italic> = 17)</td><td align="center" rowspan="1" colspan="1">14.28</td><td align="center" rowspan="1" colspan="1">11.94&#x02013;18</td><td align="center" rowspan="2" colspan="1">.00*</td></tr><tr><td align="left" rowspan="1" colspan="1">Without vascular involvement (<italic>n</italic> = 19)</td><td align="center" rowspan="1" colspan="1">10.75</td><td align="center" rowspan="1" colspan="1">6.43&#x02013;16</td></tr></tbody></table><table-wrap-foot><fn><p>						<italic>P</italic>* &#x0003c; .05 by Mann-Whitney <italic>U</italic> test. Data are presented as median values and their individual ranges.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab9" position="float"><label>Table 9</label><caption><p>Comparison of Hcy between groups of active and inactive patients according to the presence ofindividual clinical manifestations and positive pathergy.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">No. of patients</th><th align="center" colspan="2" rowspan="1">Hcy levels (<italic>&#x003bc;</italic>mol/L)</th><th align="center" rowspan="2" colspan="1"><italic>P</italic>-values</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Active</th><th align="center" rowspan="1" colspan="1">Inactive</th><th align="center" rowspan="1" colspan="1">Active</th><th align="center" rowspan="1" colspan="1">Inactive</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Vascular involvement</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">26 (19&#x02013;39.25)</td><td align="center" rowspan="1" colspan="1">14.28 (11.94&#x02013;18)</td><td align="center" rowspan="1" colspan="1">.00*</td></tr><tr><td align="left" rowspan="1" colspan="1">Oral ulcer</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">20.85 (13.7&#x02013;39.25)</td><td align="center" rowspan="1" colspan="1">11.94 (8&#x02013;14)</td><td align="center" rowspan="1" colspan="1">.00*</td></tr><tr><td align="left" rowspan="1" colspan="1">Arthritis/arthralgia</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">19 (13.7&#x02013;19)</td><td align="center" rowspan="1" colspan="1">10.83 (6.43&#x02013;17)</td><td align="center" rowspan="1" colspan="1">.00*</td></tr><tr><td align="left" rowspan="1" colspan="1">EN/PPE</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">19 (13.7&#x02013;38.1)</td><td align="center" rowspan="1" colspan="1">12.36 (8.1&#x02013;16)</td><td align="center" rowspan="1" colspan="1">.00*</td></tr><tr><td align="left" rowspan="1" colspan="1">Positive pathergy</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">20.85 (13.7&#x02013;38.1)</td><td align="center" rowspan="1" colspan="1">14.28 (7.91&#x02013;17.21)</td><td align="center" rowspan="1" colspan="1">.00*</td></tr></tbody></table><table-wrap-foot><fn><p>						<italic>P</italic>* &#x0003c; .05 by Mann-Whitney <italic>U</italic> test. Data are presented as median values and their individual ranges.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>